Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Biomaterials. 2018 Aug 21;183:128–138. doi: 10.1016/j.biomaterials.2018.08.049

Figure 1.

Figure 1.

dNP2 delivers protein into primary human T cells with higher efficiency compared to TAT. (A-D) EL4 cells, mouse splenocytes, Jurkat cells, and human peripheral blood mononuclear cells (PBMCs) were incubated in the presence of 5 μM of EGFP, TAT-EGFP, dNP2-EGFP or PBS. After 1 h, the mouse splenocytes and human PBMCs were stained with anti-mouse CD4 or anti-human CD4 fluorescently-labelled antibodies. All cells were analyzed by flow cytometry. (E-F) PBS, 1 or 5 μM of EGFP, TAT-EGFP, or dNP2-EGFP were used to treat human PBMCs. After 1 h, the cells were stained with anti-human CD4 and anti-human CD8 fluorescently-labelled antibodies. The cells were analyzed by flow cytometry. Bar graphs are presented as the mean ± s.d. (B,D) Two-way ANOVA was used for statistical analysis and *** indicates p < 0.001, n.s. indicates non-significant. (F) One-way ANOVA was used for statistical analysis and *** indicates p<0.001. Relative MFI indicates mean fluorescence intensity (MFI) normalized with the MFI of PBS treated cells.